艾伯维IL-23抑制剂再获FDA批准，治疗溃疡性结肠炎

Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors [1] - The biopharmaceutical sector is rated as Neutral [1] - Other medical sectors are also rated as Neutral [1] Core Insights - The report maintains a positive outlook on the pharmaceutical industry, expecting it to outperform the CSI 300 index by more than 5% over the next six months [7] - AbbVie’s IL-23 inhibitor has received FDA approval for treating moderate to severe active ulcerative colitis, marking it as the first approved treatment for this condition [4][6] - The pharmaceutical sector experienced a decline of 1.19% on June 19, 2024, underperforming the CSI 300 index by 0.71 percentage points, ranking 22nd among 31 sub-industries [3] Summary by Sections Industry News - AbbVie announced that the FDA has approved Skyrizi (Risankizumab) for an expanded indication to treat moderate to severe active ulcerative colitis in adults, making it the first IL-23 specific inhibitor approved for this condition [4] Company News - Notable company announcements include: - Nuotai Bio expects a net profit of 180-250 million yuan for the first half of 2024, a year-on-year increase of 330.08% to 497.34% [5] - Jichuan Pharmaceutical received approval for a new drug registration certificate for a second-generation H1 receptor antagonist [5] - Dizhe Pharmaceutical announced the approval of its new drug for treating relapsed or refractory peripheral T-cell lymphoma [5] - Xinhua Pharmaceutical received approval for pregabalin capsules, used for treating postherpetic neuralgia and fibromyalgia [5]